NASDAQ:GLTO Galecto (GLTO) Stock Price, News & Analysis $0.58 +0.02 (+3.57%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.56▼$0.5950-Day Range$0.46▼$0.6352-Week Range$0.46▼$3.45Volume58,550 shsAverage Volume195,354 shsMarket Capitalization$15.72 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Galecto alerts: Email Address Galecto MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside655.9% Upside$4.33 Price TargetShort InterestHealthy0.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.06) to ($1.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector473rd out of 936 stocksPharmaceutical Preparations Industry216th out of 436 stocks 3.1 Analyst's Opinion Consensus RatingGalecto has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageGalecto has only been the subject of 1 research reports in the past 90 days.Read more about Galecto's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.02% of the float of Galecto has been sold short.Short Interest Ratio / Days to CoverGalecto has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galecto has recently decreased by 90.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalecto does not currently pay a dividend.Dividend GrowthGalecto does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLTO. Previous Next 3.3 News and Social Media Coverage News SentimentGalecto has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Galecto this week, compared to 0 articles on an average week.Search Interest7 people have searched for GLTO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galecto insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.20% of the stock of Galecto is held by institutions.Read more about Galecto's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galecto are expected to decrease in the coming year, from ($1.06) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galecto is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galecto is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalecto has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galecto's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Galecto Stock (NASDAQ:GLTO)Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Read More GLTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLTO Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comMinerva Neurosciences Inc (4MNA.BE)May 3, 2024 | investorplace.comGLTO Stock Earnings: Galecto Beats EPS for Q1 2024July 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 1, 2024 | globenewswire.comGalecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with PembrolizumabApril 22, 2024 | theglobeandmail.com6 Stocks Positioned to Soar as Investors Focus on MASHMarch 15, 2024 | msn.comGLTO Stock Earnings: Galecto Beats EPS for Q4 2023February 16, 2024 | thestreet.comGalecto Inc.February 14, 2024 | finance.yahoo.comGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?July 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.January 9, 2024 | finance.yahoo.comWhat Makes Galecto, Inc. (GLTO) a New Strong Buy StockDecember 23, 2023 | finanznachrichten.deGalecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisDecember 22, 2023 | msn.comNike, AAR And 3 Stocks To Watch Heading Into FridayDecember 21, 2023 | finance.yahoo.comTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisOctober 23, 2023 | finance.yahoo.comGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialOctober 5, 2023 | msn.comGalecto (GLTO) Price Target Increased by 13.16% to 5.48October 2, 2023 | finanznachrichten.deGalecto, Inc.: Galecto Announces Plans to Explore Strategic AlternativesSeptember 30, 2023 | msn.comHC Wainwright & Co. Downgrades Galecto (GLTO)September 27, 2023 | bizjournals.comWeeks after dropping lung disease drug, Galecto lays off most of staff, explores saleSee More Headlines Receive GLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/29/2024Today7/26/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLTO CUSIPN/A CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$4.33 High Stock Price Target$9.00 Low Stock Price Target$2.00 Potential Upside/Downside+638.2%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.11% Return on Assets-68.68% Debt Debt-to-Equity RatioN/A Current Ratio7.07 Quick Ratio7.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book0.49Miscellaneous Outstanding Shares27,110,000Free Float23,832,000Market Cap$15.91 million OptionableOptionable Beta1.18 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Hans T. Schambye M.D. (Age 58)Ph.D., Co-Founder, President, CEO & Director Comp: $700.13kMr. Jonathan P. Freve CPA (Age 46)CPA, Chief Financial Officer Comp: $604.93kMr. Ulf J. NilssonCo-FounderDr. Hakon LefflerCo-FounderProf. Tariq Sethi B.Sc.FRCP, M.A., M.D., Ph.D., Co-FounderMr. Garrett Winslow Esq. (Age 45)Senior VP, General Counsel & Corporate Secretary More ExecutivesKey CompetitorsLiminal BioSciencesNASDAQ:LMNLEyenoviaNASDAQ:EYENProPhase LabsNASDAQ:PRPHAileron TherapeuticsNASDAQ:ALRNCelularityNASDAQ:CELUView All CompetitorsInsidersOrbimed Advisors LlcSold 209,400 sharesTotal: $628,200.00 ($3.00/share)View All Insider Transactions GLTO Stock Analysis - Frequently Asked Questions How have GLTO shares performed this year? Galecto's stock was trading at $0.72 at the beginning of 2024. Since then, GLTO stock has decreased by 20.4% and is now trading at $0.5733. View the best growth stocks for 2024 here. How were Galecto's earnings last quarter? Galecto, Inc. (NASDAQ:GLTO) released its earnings results on Monday, April, 29th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.21. When did Galecto IPO? Galecto (GLTO) raised $86 million in an IPO on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Galecto? Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLTO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.